Sector News

Ferring buys BioSET’s orthobiologics

February 19, 2015
Life sciences
Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair.
 
The candidates in question, Amplex and Prefix, are based on “a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair”, Ferring says. They will be investigated for fusion in foot/ankle and lumbar spine surgical procedures, respectively.
 
Orthopaedics has become a key area for Ferring since the 2005 launch of Euflexxa (1% sodium hyaluronate) for knee pain and buying the BioSET portfolio builds on that. Chief operating officer Michel Pettigrew said that “by developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery”.
 
No financial terms have been disclosed. Switzerland-headquartered Ferring noted that each year some two million procedures involving bone graft materials, including 700,000 fusions, are performed in the USA alone.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]